| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,782 |
5,834 |
$775K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,182 |
3,380 |
$736K |
| 80053 |
Comprehensive metabolic panel |
8,007 |
6,489 |
$373K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,097 |
825 |
$322K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,582 |
5,979 |
$212K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
211 |
168 |
$202K |
| 70450 |
Computed tomography, head or brain; without contrast material |
267 |
200 |
$129K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,163 |
1,521 |
$129K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,745 |
1,308 |
$113K |
| 84484 |
|
1,482 |
992 |
$106K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,390 |
1,238 |
$97K |
| 80061 |
Lipid panel |
2,129 |
1,773 |
$94K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,282 |
1,929 |
$91K |
| 83690 |
|
1,758 |
1,366 |
$87K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,583 |
1,220 |
$87K |
| 36415 |
Collection of venous blood by venipuncture |
8,377 |
6,469 |
$84K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
108 |
96 |
$83K |
| 0099U |
|
70 |
63 |
$80K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,518 |
1,108 |
$70K |
| 71046 |
Radiologic examination, chest; 2 views |
924 |
758 |
$70K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
831 |
568 |
$68K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,844 |
1,370 |
$65K |
| 71045 |
Radiologic examination, chest; single view |
1,005 |
788 |
$53K |
| 82248 |
|
1,345 |
1,025 |
$51K |
| 85027 |
|
1,947 |
1,515 |
$47K |
| 82550 |
|
1,127 |
781 |
$45K |
| 83605 |
|
1,516 |
1,089 |
$40K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
215 |
208 |
$37K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,286 |
1,841 |
$34K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
200 |
169 |
$33K |
| 83735 |
|
812 |
660 |
$33K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
169 |
153 |
$32K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
224 |
208 |
$30K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
141 |
116 |
$28K |
| 81003 |
|
862 |
691 |
$26K |
| 81001 |
|
1,150 |
950 |
$25K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
335 |
253 |
$25K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
300 |
176 |
$25K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
899 |
737 |
$24K |
| 82553 |
|
310 |
202 |
$24K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,157 |
825 |
$23K |
| 73630 |
|
249 |
222 |
$19K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
488 |
332 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
353 |
260 |
$15K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
164 |
147 |
$13K |
| 84703 |
|
450 |
372 |
$12K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
258 |
144 |
$11K |
| J2704 |
Injection, propofol, 10 mg |
132 |
110 |
$11K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
339 |
272 |
$10K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
98 |
71 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
215 |
188 |
$8K |
| 87040 |
|
77 |
52 |
$7K |
| 73030 |
|
42 |
39 |
$6K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
14 |
14 |
$6K |
| 85379 |
|
157 |
113 |
$6K |
| 85007 |
|
350 |
249 |
$6K |
| 87081 |
|
163 |
144 |
$5K |
| 73610 |
|
62 |
57 |
$5K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
68 |
43 |
$4K |
| 73130 |
|
42 |
37 |
$4K |
| 74022 |
|
24 |
14 |
$3K |
| 85610 |
|
128 |
104 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
111 |
86 |
$3K |
| 82150 |
|
57 |
38 |
$3K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
47 |
42 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
47 |
42 |
$2K |
| 87581 |
|
47 |
42 |
$2K |
| 87486 |
|
47 |
42 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
44 |
39 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
51 |
50 |
$2K |
| 86318 |
|
59 |
50 |
$2K |
| 83880 |
|
31 |
25 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
50 |
38 |
$2K |
| 87186 |
|
59 |
48 |
$2K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
73 |
57 |
$2K |
| 73564 |
|
15 |
14 |
$1K |
| J3490 |
Unclassified drugs |
1,123 |
463 |
$1K |
| 96376 |
|
37 |
12 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
62 |
39 |
$1K |
| 87070 |
|
31 |
24 |
$1K |
| 87339 |
|
15 |
14 |
$859.16 |
| 82607 |
|
14 |
12 |
$840.55 |
| 87205 |
|
31 |
25 |
$764.25 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
28 |
25 |
$622.12 |
| 83540 |
|
25 |
24 |
$620.68 |
| 85730 |
|
15 |
13 |
$570.52 |
| 81025 |
|
22 |
12 |
$295.28 |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
13 |
12 |
$287.46 |
| 85652 |
|
33 |
24 |
$279.45 |
| 86140 |
|
15 |
12 |
$140.65 |
| J2060 |
Injection, lorazepam, 2 mg |
15 |
12 |
$75.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
12 |
12 |
$31.42 |